Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib in D842-mutant GIST
NCT01243346Phase 2Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Apr 2011
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crenolanib in gastrointestinal stromal tumor (GIST), sponsored by AROG Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate at 1.5 years. Started Apr 2011; status: completed.
02
Drugs
crenolanib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01243346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01243346.